Latest news

• Novartis' Ilaris wins three new FDA approvals

  The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

• Grunenthal to market MSD’s pain drug

  The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

• Novartis wins childhood arthritis indication for Ilaris in EU

  Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

• Novartis gets FDA green light for new Ilaris indication

  Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... arthritis. Efforts to get a gouty arthritis indication in the US were knocked back in 2011, however, when the FDA -

• Novartis' Ilaris cleared for gouty arthritis in EU

  Novartis' Ilaris cleared for gouty arthritis in EU. First biologic drug approved for condition in Europe. ... Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another gain for the